Evidence map›Paper›PMID 32682948›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2020

Anaerobic Antibiotics and the Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.

John S Tanaka, Rebecca R Young, Sarah M Heston, Kirsten Jenkins, Lisa P Spees, Anthony D Sung, Kelly Corbet, Jillian C Thompson, Lauren Bohannon, Paul L Martin and 8 more

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06342115 (Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase), which is not on this map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06342115 phase4recruitingnot on this mapstarted 2025, after this paper: background citation

Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase (ESBL)-Producing Pathogens: a Randomized Double-blind Non-inferiority Trial.

TypeinterventionalSponsorBeneficência Portuguesa de São PauloRan2025 to 2026Enrolled176ConditionsFebrile NeutropeniaArmsCeftolozane-Tazobactam, Meropenem
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Impact of ExogenousAntibiotics (Basel, Switzerland) · 2024
    Article
  12. Review
  13. Article
  14. Review
  15. The Microbiome and Pediatric Transplantation.Journal of the Pediatric Infectious Diseases Society · 2024
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

John S TanakaDuke University School of Medicine, Durham, North Carolina.
Rebecca R YoungDivision of Pediatric Infectious Diseases, Duke University Medical Center, Durham, North Carolina.
Sarah M HestonDivision of Pediatric Infectious Diseases, Duke University Medical Center, Durham, North Carolina.
Kirsten JenkinsDivision of Pediatric Infectious Diseases, Duke University Medical Center, Durham, North Carolina.
Lisa P SpeesDepartment of Health Policy and Management, University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Chapel Hill, North Carolina; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Anthony D SungDivision of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, North Carolina.
Kelly CorbetDivision of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, North Carolina.
Jillian C ThompsonDivision of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, North Carolina.
Lauren BohannonDivision of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, North Carolina.
Paul L MartinDivision of Pediatric Blood and Marrow Transplant, Duke University Medical Center, Durham, North Carolina.
Andre StokhuyzenDivision of Pediatric Blood and Marrow Transplant, Duke University Medical Center, Durham, North Carolina.
Richard VinesettDivision of Pediatric Blood and Marrow Transplant, Duke University Medical Center, Durham, North Carolina.
Doyle V WardCenter for Microbiome Research, University of Massachusetts Medical School, Worcester, Massachusetts; Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts.
Shakti K BhattaraiDepartment of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts.
Vanni BucciDepartment of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts.
Mehreen ArshadDivision of Pediatric Infectious Diseases, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
Patrick C SeedDivision of Pediatric Infectious Diseases, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
Matthew S KellyDivision of Pediatric Infectious Diseases, Duke University Medical Center, Durham, North Carolina. Electronic address: matthew.kelly@duke.edu.
Duke Medical Center · USDuke University · USUniversity of Massachusetts Chan Medical School · USLurie Children's Hospital · USUniversity of North Carolina at Chapel Hill · US

Funding

Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8M
Support for QA/QC for Prior Approval ProcessUL1TR002553 · NCATS · DUKE UNIVERSITY · PI LI, JENNIFER S, MCNAMARA, JAMES O. · 2018 to 2023
$58.5M
UNC-CH TRAINING PROGRAM IN HEALTH SERVICES RESEARCHT32HS000032 · AHRQ · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HOLMES, GEORGE M · 1989 to 2024
$8.2M
Duke CTSA (Composite)KL2TR001115 · NCATS · DUKE UNIVERSITY · PI BOULWARE, LEIGH E, KRAFT, MONICA · 2013 to 2017
$5.1M
Cancer Care Quality Training ProgramT32CA116339 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ETHAN M. BASCH, Stephanie Brooke Wheeler · 2018 to 2026
$3.0M
Unified Program for Therapeutics in Children (UPTiC)T32HD094671 · NICHD · DUKE UNIVERSITY · PI Ian J Davis, Kanecia Obie Zimmerman · 2019 to 2026
$2.9M
Nasopharyngeal Microbiome and Risk of Bacterial Pathogen Colonization in InfantsK23AI135090 · NIAID · DUKE UNIVERSITY · PI KELLY, MATTHEW SCOTT · 2018 to 2022
$860k
AHRQ HHS T32 HS000032NCATS NIH HHS KL2 TR001115NCATS NIH HHS UL1 TR002553NCI NIH HHS T32 CA116339NIAID NIH HHS K23 AI135090NIAID NIH HHS UM1 AI104681NICHD NIH HHS T32 HD094671
6 · The paper itself

Abstract

Certain anaerobic bacteria are important for maintenance of gut barrier integrity and immune tolerance and may influence the risk of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). We conducted a single-center retrospective cohort study of allogeneic HSCT recipients to evaluate associations between receipt of antibiotics with an anaerobic spectrum of activity and GVHD outcomes. We identified 1214 children and adults who developed febrile neutropenia between 7 days before and 28 days after HSCT and compared GVHD risk and mortality among patients who received anaerobic antibiotics (piperacillin-tazobactam or carbapenems; n = 491) to patients who received only antibiotics with minimal activity against anaerobes (aztreonam, cefepime, or ceftazidime; n = 723). We performed metagenomic sequencing of serial fecal samples from 36 pediatric patients to compare the effects of specific antibiotics on the gut metagenome. Receipt of anaerobic antibiotics was associated with higher hazards of acute gut/liver GVHD (hazard ratio [HR], 1.26; 95% confidence interval [CI], 1.03 to 1.54) and acute GVHD mortality (HR, 1.63; 95% CI, 1.08 to 2.46), but not chronic GVHD diagnosis (HR, 1.04; 95% CI: .84 to 1.28) or chronic GVHD mortality (HR, .88; 95% CI, .53 to 1.45). Anaerobic antibiotics resulted in decreased gut bacterial diversity, reduced abundances of Bifidobacteriales and Clostridiales, and loss of bacterial genes encoding butyrate biosynthesis enzymes from the gut metagenome. Acute gut/liver GVHD was preceded by a sharp decline in bacterial butyrate biosynthesis genes with antibiotic treatment. Our findings demonstrate that exposure to anaerobic antibiotics is associated with increased risks of acute gut/liver GVHD and acute GVHD mortality after allogeneic HSCT. Use of piperacillin-tazobactam or carbapenems should be reserved for febrile neutropenia cases in which anaerobic or multidrug-resistant infections are suspected.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationAdultAnaerobiosisAnti-Bacterial AgentsChildHumansRetrospective StudiesTransplantation, HomologousAnti-Bacterial AgentsCarbapenemsFebrile neutropeniaGut microbiomePiperacillin-tazobactam

Identifiers

PMID32682948
PMCPMC7609492
OpenAlexW3043709758

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.